AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 163 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.72 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $4,981,000 | -12.4% | 80,920 | -3.9% | 0.06% | -12.5% |
| Q2 2018 | $5,685,000 | +58.5% | 84,165 | +27.3% | 0.07% | +56.5% |
| Q1 2018 | $3,586,000 | -59.3% | 66,105 | -55.2% | 0.05% | -54.0% |
| Q4 2017 | $8,817,000 | +67.3% | 147,570 | +36.1% | 0.10% | +63.9% |
| Q3 2017 | $5,271,000 | -21.3% | 108,450 | -14.9% | 0.06% | -23.8% |
| Q2 2017 | $6,697,000 | +62.5% | 127,450 | +40.2% | 0.08% | +60.0% |
| Q1 2017 | $4,122,000 | +43.5% | 90,900 | +19.8% | 0.05% | +35.1% |
| Q4 2016 | $2,873,000 | -12.4% | 75,900 | -12.7% | 0.04% | -5.1% |
| Q3 2016 | $3,280,000 | +120.4% | 86,900 | +2.7% | 0.04% | +333.3% |
| Q2 2016 | $1,488,000 | +194.1% | 84,600 | +103.5% | 0.01% | +28.6% |
| Q1 2016 | $506,000 | -47.2% | 41,575 | +5.5% | 0.01% | -46.2% |
| Q4 2015 | $959,000 | +97.3% | 39,400 | +43.8% | 0.01% | +85.7% |
| Q3 2015 | $486,000 | +18.2% | 27,400 | +109.0% | 0.01% | +40.0% |
| Q1 2015 | $411,000 | +73.4% | 13,112 | +61.6% | 0.01% | +66.7% |
| Q4 2014 | $237,000 | – | 8,112 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |